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Abstract 16 
Brucella infection is frequently acquired through the respiratory route. The pathogen 17 
disseminates systemically from the lungs to infect peripheral organs. In this review 18 
we summarize the existing data on the pathogenesis of inhalational Brucella 19 
infection, the pulmonary immune response to the pathogen, and potential strategies 20 
for inducing protective lung immunity. 21 
 22 





1. Clinical aspects and transmission of brucellosis  26 
Brucellosis is an infectious disease caused by Gram-negative, facultative intracellular 27 
bacteria of the genus Brucella, that affects several species of domestic animals, 28 
wildlife and humans, with a significant impact on public health. Brucella invades, 29 
replicates and survives efficiently in phagocytic and several non-phagocytic cells 30 
causing chronic disease [1–3]. Brucellosis is the most common zoonosis, with more 31 
than 500,000 new reported human cases annually, and has a worldwide distribution, 32 
mainly affecting the Mediterranean countries, Central Asia, India, Arabic Peninsula, 33 
and Central and Latin America [4,5]. Brucellosis is a debilitating but rarely fatal 34 
disease. Acute human disease is characterized by non-pathognomonic clinical 35 
findings such as undulant fever, night sweats, splenomegaly, weight loss, myalgia, 36 
arthralgia and depression. Chronic disease can cause more severe complications 37 
such as osteoarticular brucellosis, neurobrucellosis and endocarditis, the latter being 38 
the main cause of the occasional fatal cases [6]. B. melitensis, B. suis and B. abortus 39 
are the most pathogenic species for humans and each one has a domestic animal as 40 
preferential host (small ruminants, swine, and bovines, respectively). In domestic 41 
animals, brucellosis causes reproductive diseases characterized by abortions, 42 
stillbirth, orchitis, epididymitis and infertility, causing severe economic losses in 43 
animal industry. It should be noted that there are no vaccines for human brucellosis, 44 
so the prevention of infection in humans depends almost exclusively on the control of 45 
infection in domestic animals through vaccination and other sanitary measures. 46 
Brucella spp. usually enters its hosts through the mucosa. Human infection 47 
associated with consumption of unpasteurized dairy products has been widely 48 
documented [7,8], and there are also reports of contagion by contact of contaminated 49 
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material with the ocular conjunctiva [9,10]. Inhalation of infected aerosols is a 50 
frequent way to acquire the infection in humans. Outbreaks of human brucellosis 51 
linked to airborne transmission have been reported in slaughterhouses, laboratories 52 
producing  Brucella  vaccines, and rural areas [11–14]. Brucellosis is considered the 53 
most common laboratory-acquired infection worldwide [15,16], and airborne 54 
transmission have been implicated in most cases. Mucosal entry is also the main 55 
form of infection among susceptible animals. In particular, the animals' habit of 56 
sniffing and licking the placental and fetal remains from abortions, which in case of 57 
coming from a Brucella abortion are contaminated with a very high load of bacteria, 58 
contributes significantly to the spread of infection in the herds. In some species, 59 
particularly goats, swine and dogs, spread through the venereal route is also 60 
important. 61 
Human brucellosis can be easily acquired by air transmission and therefore 62 
Brucella can be considered a possible biological weapon. B. suis was the first agent 63 
weaponized by the United States, in the 1950s [4,17]. It has been estimated that as 64 
few as 10 to 100 aerosolized organisms are required to generate disease in humans. 65 
The high infective capacity of Brucella when delivered in this manner, its ability to 66 
spread easily, and the chronic and debilitating nature of human disease has led to 67 
the Centers for Disease Control and Prevention and the National Institute of Allergy 68 
and Infectious Diseases to classify B. melitensis, B. abortus, and B. suis as Category 69 
B bioterrorism agents [4,17].  70 
Although Brucella spp. enters the body very frequently through the respiratory 71 
tract, most studies on Brucella pathogenesis and immunity have been conducted in 72 
animal models of intraperitoneal infection and to a lesser extent in models of oral 73 
infections. However, in the last decade some studies have begun to elucidate the 74 
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host-pathogen interaction during Brucella respiratory infection. In this review we will 75 
discuss the existing data on the pathogenesis of Brucella infection acquired through 76 
the respiratory route, the pulmonary immune mechanisms against such infection, and 77 
potential strategies for inducing protective lung immunity. 78 
 79 
2. Pulmonary brucellosis in humans 80 
Respiratory manifestations are relatively infrequent in human brucellosis, even in 81 
patients with documented or strongly presumed airborne infection. A distinction must 82 
be made between pulmonary involvement in cases of airborne transmission and that 83 
occurring in patients with brucellosis acquired through other infection routes. In the 84 
first case, the pathogen reaches the lungs from the alveolar space and establishes 85 
early interactions with alveolar epithelial cells and macrophages, which are the first 86 
cells involved in the local immune response to this infection. From this location the 87 
bacterium disseminates systemically to establish infection in peripheral organs. In the 88 
second scenario, in contrast, the pathogen has previously interacted with the 89 
systemic immune effectors and has probably established infection in other organs 90 
before reaching the lung through hematogenous dissemination. It may be speculated 91 
that these differences between the infection routes may eventually translate into 92 
differences in the pathological phenomena taking place in the lung during pulmonary 93 
brucellosis.  94 
As mentioned, airborne transmission of Brucella has been linked to human 95 
cases in slaughterhouses, clinical microbiology laboratories, vaccine production 96 
plants, and rural areas [11–16]. A large study by Kauffmann et al. analyzed the data 97 
from 6 brucellosis outbreaks (387 cases) occurred in the 1960-1976 period in 98 
abattoirs in USA and clearly established the airborne nature of the disease, but 99 
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clinical manifestations were not described [12]. Other studies on airborne brucellosis 100 
report clinical data and a few provide information on respiratory involvement. Typical 101 
manifestations of brucellosis (fever, myalgia, adenopathies, etc.) were found in 8 102 
patients presumably infected through aerosols in a clinical microbiology laboratory, 103 
but pneumonitis was detected in only one of them (12%) [13]. In a review of 60 cases 104 
of laboratory-acquired brucellosis registered in the USA from 1945 to 1957, 21 of 105 
which occurred after documented laboratory accidents, cough was found in 33% and 106 
pulmonary rales in 8.3% [18]. Unfortunately, no details were provided about the 107 
nature of the accidents to establish the likelihood of airborne transmission. An 108 
outbreak of airborne infection in a laboratory producing B. melitensis Rev-1 vaccine 109 
involved 22 symptomatic patients, most of which presented the typical brucellosis 110 
manifestations. Of note, however, 6 of them presented epistaxis [19]. Airborne 111 
transmission was considered the most likely route of infection for 33 rural workers 112 
infected with B. melitensis in Argentina, from which 9.1% had pneumonitis and 113 
bronchitis [14]. Only general brucellosis findings were reported in other cases of 114 
probable airborne brucellosis, including 4 patients from a clinical microbiology 115 
laboratory [20], 3 workers that got the infection from sniffing Brucella cultures [21], 116 
and 12 employees from a laboratory in which a flask containing a Brucella culture 117 
was accidentally broken [22]. A review of laboratory-acquired brucellosis cases 118 
reported in the literature from 1982 to 2007 identified 59 cases linked to aerosol 119 
exposure (83% of 71 total cases) [16]. The study also analyzed separately 121 cases 120 
of airborne brucellosis previously reported in summary reports. In both groups of 121 
patients, the most frequent clinical findings were fever, arthralgia, sweats, headache, 122 
myalgia and malaise. No pulmonary findings were reported.  123 
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Other case reports and reviews have described the clinical and pathological 124 
findings in brucellosis cases exhibiting pulmonary involvement, regardless of the 125 
route of infection. Moreover, in most of these cases the route of infection is unknown. 126 
The most recent review on this subject, performed by Solera and Solís García del 127 
Pozo [23], has collected data from case reports and also from three major previous 128 
reviews performed by Pappas et al. [24], Hatipoglu et al. [25] and Erdem et al. [26]. 129 
The study only included brucellosis patients with respiratory involvement confirmed 130 
by radiography or computed tomography (n= 253). Cough was present in about 64% 131 
of the patients from case reports, and in 45-86% of patients in the three main 132 
previous reviews. Expectoration was reported by around 32% and 27-32%, 133 
respectively, and dyspnea was reported by 21% and 21-61%. Chest pain was 134 
present in 33% of the patients in case reports but was much less frequent in the 135 
previous reviews. In the case reports the most frequent radiological manifestation 136 
was pleural effusion (47.2%), followed by pneumonia (41.7%), pulmonary nodules 137 
(19.4%), interstitial pattern (18.1%) and mediastinal or thoracic lymph nodes (9.7%). 138 
The main radiological pattern found in the three previous reviews varied from 139 
pneumonia (68.4%) [26] to interstitial pattern (40.5%) [24] or pulmonary nodules 140 
(48.6%) [25]. In the few cases reporting histopathological data, granulomatous 141 
lesions were described.  142 
 143 
3. Course of respiratory Brucella infection in animal models 144 
The fact that the respiratory mucosa serves as a natural site of entry of Brucella to 145 
the host, and the potential use of this bacterium as a biological weapon agent, has 146 
led to the development of animal models of respiratory infection to evaluate the 147 
efficacy of novel vaccines and treatments for brucellosis. The mouse has been the 148 
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most extensively animal model to asses these topics due to its easy handling in 149 
laboratories despite not being a natural host. Intranasal (i.n.), intratracheal (i.t.), 150 
nose-only and whole-body aerosol routes of challenge have been used to establish 151 
brucellosis in Balb/c mice [27–32]. In all the inoculation routes studied, Brucella could 152 
rapidly disseminate from the site of challenge to the spleen and liver. 153 
B. abortus infection of mice via the whole-body aerosol route results in rapid 154 
colonization of lung tissue that is sustained or increases during the first weeks post-155 
challenge and then gradually decreases over time, indicating the ability of this 156 
pathogen to replicate within the lung [31]. A similar behavior was observed when B. 157 
suis was used for challenge [30,33]. In contrast, B. melitensis 16M inoculated by 158 
different routes colonizes the lungs but does not replicate in these organs, and the 159 
count of viable bacteria remains constant or decreases over time depending on the 160 
doses received [27,30–32]. In addition, viable bacteria are detected in the lungs at 161 
prolonged times after infection (8 weeks post-challenge) [31,32]. This suggests that 162 
the lung is a persistence niche for Brucella in the host. Surprisingly, no significant 163 
histological changes are observed in the lungs of B. abortus- or B. melitensis-infected 164 
mice [27,28]. Henning et. al. described perivascular or peribronchiolar mononuclear 165 
cell infiltration in only 17% of the animals infected by the aerosol route at the highest 166 
dose tested [32]. The limited inflammatory immune response to Brucella in the lungs 167 
may be due in part to the ability of the pathogen to actively modulate the pulmonary 168 
innate immune response as described by Hielpos et al. [28] (see below). 169 
B. abortus, B. melitensis and B. suis administered by different routes of 170 
exposure (i.n., i.t., nose-only and whole-body aerosol routes) can be found in the 171 
spleen of infected animals in the first or second week post-challenge depending on 172 
the time tested and the doses used [27–33]. In contrast to what occurs in the lung, 173 
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the load of B. melitensis in the spleen increases until week 4 post-challenge and then 174 
decreases [31]. Similar results were described for B. suis [30,33]. Conversely, the 175 
burden of B. abortus in the spleen increases steadily over time until the end of the 176 
experiments (8 weeks post-challenge) [31]. As mentioned, splenomegaly is a 177 
common clinical manifestation of human brucellosis. Splenomegaly was evident in 178 
animals infected by the i.n. route or whole-body aerosol routes with B. melitensis at 3 179 
or 4 weeks after challenge, respectively [27,31]. Histological evaluation of the 180 
spleens of these animals showed an increase in the white pulp and the marginal 181 
zone [27]. Whole-body aerosol infection with B. abortus also generated 182 
splenomegaly but this was evident later (6 weeks post-challenge) [31]. 183 
The liver is another target organ during Brucella respiratory infection. B. 184 
abortus, B. melitensis and B. suis was detected in liver during the first weeks after 185 
challenge and increased over time [27,30,31,33]. Consistently with human disease, 186 
B. melitensis respiratory infection causes inflammation in the liver [27,32]. It is still 187 
unknown whether respiratory infection with B. abortus or B. suis causes histological 188 
lesions in this organ. Notably, Smither et al. have described that B. suis and B. 189 
melitensis also have tropism for the uterus in mice challenged by aerosolization [30]. 190 
These results are consistent with the detection of bacteria in the reproductive 191 
systems of ruminants and in the uterus of other naturally infected animals, such as, 192 
otters and seals [34]. Although fever is one of the most common symptoms of human 193 
disease, increases in body temperature have not been detected during nose-only 194 
aerosol infection with B. melitensis [32]. In concordance to human disease, bacteria 195 
were isolated from the blood of some infected mice. Positive blood cultures were 196 
variable, reaching 62% of infected mice at the highest dose tested. These positive 197 
cultures were observed only after blood samples were enriched prior to plating [32]. 198 
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In the same report, endocarditis was observed in 8% of challenged mice, which is 199 
consistent with this rare complication being observed in human patients. 200 
Non-human primates have also been used as models for Brucella infection 201 
due to their similar susceptibility to infectious diseases as compared to humans. 202 
Several studies demonstrated that rhesus macaques are susceptible to aerosolized 203 
B. melitensis infection, as demonstrated by systemic dissemination from the 204 
challenge sites and histology [35–37]. This animal model has not been used to 205 
assess susceptibility to respiratory infection by B. abortus, and only one study 206 
analyzed tissue burden for the first week after aerosol exposure with a high dose of 207 
B. suis 1330 [38]. In contrast to what occurs in the murine model, rhesus macaques 208 
that received an aerosol challenge with B. melitensis or B. suis developed undulating 209 
fever [37,38]. The bacteria quickly spread from the challenge site to the liver, spleen 210 
and kidneys, among other tissues [35–37]. The burden of B. melitensis in the lung, 211 
liver, kidneys and spleen was greatest on day 14 post-challenge and decreased over 212 
time. At the end of the study (day 56 post-challenge) bacteria were still detected in 213 
the organs, although at very low values [37]. However, it is still unknown whether 214 
rhesus macaques develop sterilizing immunity or if they are chronically infected with 215 
a few bacteria. Positive blood cultures were observed after challenge by B. melitensis 216 
in 50% of infected animals [35,37]. Histopathologic examination revealed lesions 217 
attributed to Brucella infection in the liver, kidneys, lymph nodes, lungs, and/or spleen 218 
of all animals [35–38]. Splenomegaly was reported in all studies of aerosolized B. 219 
melitensis. Mense et al. demonstrated the presence of B. melitensis and 220 
inflammatory lesions in the testes and epididymis of some infected macaques [35], 221 
which is similar to human brucellosis, in which the Brucella location in the male 222 
reproductive tract is observed in approximately 2% to 10% of reported cases. In other 223 
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study, B. melitensis was cultured from the saliva and vaginal vault of infected 224 
animals, demonstrating bacterial dissemination to other target tissues [39]. Infection 225 
with aerosolized B. melitensis only generates changes in some clinical laboratory 226 
parameters, such as an increase in C-reactive protein and in certain liver enzymes, 227 
which is consistent with what has been observed in human brucellosis [37].  228 
Guinea pigs have been also used since the beginning of the 20th century to 229 
assess the pathogenicity of respiratory infection with B. suis and B. melitensis. As in 230 
the murine model, B. suis replicated in the lungs of guinea pigs infected by the 231 
aerosol route [40,41]. Bacterial dissemination from lungs to peripheral organs only 232 
occurred when the bacteria have reached the regional lymph nodes and blood [40]. 233 
The burden in the spleen increased from day 11 until day 28 post-challenge, and 234 
then decreased. At the end of the study (215 days post-challenge) viable bacteria 235 
were still detected in the spleen of some animals. Splenomegaly developed in all 236 
infected animals and macroscopic lesions were observed in the spleen and the 237 
bronchial and cervical lymph nodes. Macroscopic lesions were evident in the lungs 238 
only after day 96 post-challenge. Recently, Hensel et al. demonstrated that B. 239 
melitensis, inoculated in guinea pigs by the i.t. route in high doses (107-109), 240 
colonizes the spleen, the uterus and the tracheobronchial and cervical lymph nodes 241 
as early as 2 hours post-challenge [42]. B. melitensis does not replicate in the lung 242 
and the number of bacteria decreases with time post-infection (p.i.). In contrast, the 243 
bacterial burden in the liver, uterus, spleen, and cervical and tracheobronchial lymph 244 
nodes increases over time. Notably, inoculation of a low dose of B. melitensis (101 245 
and 102 CFU) in guinea pigs did not result in colonization of any tissue examined. 246 
Animals infected with the highest dose developed fever, splenomegaly and 247 
histological changes in the all tissue evaluated [42].   248 
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In summary, the studies described demonstrate that guinea pigs and rhesus 249 
macaques infected through the respiratory route develop characteristic signs and 250 
symptoms of the disease that mimic human brucellosis and therefore support the use 251 
of these animal models to assess the efficacy of new vaccines and therapies against 252 
Brucella inhalational infection. 253 
 All these studies clearly demonstrate that Brucella can reach the bloodstream 254 
and peripheral organs from its initial site of entry in the lungs. The mechanisms used 255 
by the pathogen to cross the lung epithelial barrier and gain access to the blood 256 
and/or lymphatic circulation in order to disseminate have not been clarified. 257 
Respiratory pathogens have evolved many strategies to interfere with cell-cell 258 
junctions, increase epithelial permeability, destabilize epithelial structure and 259 
function, and sometimes cross and/or break the barrier that constitutes the epithelium 260 
[43]. It has been shown that Brucella spp. can adhere and invade human bronchial 261 
and alveolar epithelial cells [44]. While rough strains (Brucella canis and Brucella 262 
abortus RB51) are internalized more efficiently than smooth strains (B. abortus 2308 263 
and Brucella suis 1330), only the latter replicate intracellularly. The expression of the 264 
type IV secretion system (T4SS) encoded by virB genes is essential for the 265 
intracellular replication of Brucella in lung epithelial cells. However, this infection does 266 
not seem to induce significant respiratory epithelial cells death.  267 
 For some infections by airborne bacteria that can survive inside macrophages, 268 
it has been postulated that infected alveolar macrophages (AM) could migrate to the 269 
systemic circulation carrying viable pathogens that can later establish infection at 270 
distant sites, thus constituting a Trojan horse mechanism [45]. Of note, a study by 271 
Archambaud et al. in mice infected with B. abortus through the intranasal route 272 
showed that AM harboring live brucellae migrate within a few days p.i. to the lung-273 
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draining mediastinal lymph nodes where intracellular replication of the pathogen 274 
takes place [46]. Therefore, this study suggested that Brucella can replicate 275 
intracellularly in AM and that these cells can act as Trojan horses for bacterial 276 
dissemination. Later in vitro studies confirmed the ability of smooth Brucella species 277 
to survive and replicate in murine AM and porcine AM [47,48]. However, the survival 278 
and replication of brucellae in AM seems to vary with the Brucella species and the 279 
host species. While B. suis was able to invade and replicate in AM from hooded 280 
seals (Cystophora cristata), different strains of B. ceti and B. pinnipedialis were able 281 
to invade but not to establish a persistent infection in these cells [49].  282 
 283 
4. Immune response to respiratory Brucella infection 284 
4.1. Innate immune response 285 
Once inhaled, Brucella microorganisms may interact with the respiratory epithelium, 286 
the AM and, later, the underlying fibroblasts. All these cell types have immunological 287 
relevance, due to their ability to internalize bacteria and, eventually, produce 288 
antigenic presentation, and/or due to their ability to produce mediators (cytokines, 289 
chemokines, antimicrobial peptides, etc.) in response to bacterial antigens and/or to 290 
cytokines produced by other cells [50]. 291 
In addition to its function as a physical barrier between the airway lumen and 292 
blood circulation, the airway epithelium also displays immunological activities. Human 293 
bronchial epithelial cells secrete IL-8, MCP-1, CCL20 and GM-CSF upon infection 294 
with B. abortus. Alveolar epithelial cells do not secrete IL-8 or MCP-1 but secrete 295 
CCL20 in response to the infection [51,52]. Notably, most of these responses are 296 
also produced by B. abortus antigens. Bronchial epithelial cells secrete IL-8, CCL20 297 
and GM-CSF after stimulation with heat-killed B. abortus (HKBA), cytoplasmic 298 
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proteins and LPS from B. abortus, whereas alveolar epithelial cells secrete CCL20 in 299 
response to a lipidated outer membrane protein from B. abortus (L-Omp19) 300 
demonstrating that Brucella antigens can induce per se the secretion of chemokines 301 
and growth factors by lung epithelia [51,52]. 302 
Human lung epithelial cells are known to secrete beta-defensins (hBD) with 303 
antimicrobial properties, either constitutively (hBD1) or in response to infections with 304 
respiratory pathogens. Human alveolar epithelial cells do not secrete hBD2 in 305 
response to B. abortus infection, but secretion is induced in response to factors 306 
secreted by Brucella-infected monocytes (IL-1β) [52] (see below). Nevertheless, 307 
hBD2 and hBD3 have no bactericidal activity against B. abortus even at levels much 308 
higher than those required to kill Escherichia coli. 309 
In close contact with the alveolar epithelium are AM, the main phagocytic 310 
immune cells in lung [53]. In response to B. abortus infection murine AM secret TNF-311 
α, KC (CXCL1, neutrophil chemoattractant), IL-1β, IL-6 and IL-12, albeit at lower 312 
levels than peritoneal macrophages [47]. Studies using knockout (KO) mice for TLR 313 
receptors revealed that TNF-α and KC responses are mediated by TLR2 recognition. 314 
In contrast, a cell line of porcine AM does not seem to produce TNF-α in response to 315 
B. suis infection, and this appears to be related to modulation by a bacterial outer 316 
membrane protein (Omp25) [48]. This diminished TNF-α response correlates with an 317 
enhanced survival of wild type B. suis in porcine AM as compared to a Δomp25 318 
mutant. 319 
While the responses described above have been evaluated using single cell 320 
types (either epithelial cells or AM), in the in vivo situation a crosstalk between lung 321 
epithelial cells and AM or other macrophagic populations can take place and may be 322 
an important step to mount an immune response after Brucella inhalation. B. abortus-323 
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infected cocultures of human bronchial or alveolar epithelial cells and monocytes 324 
release IL-8 and/or MCP-1 in higher levels than those produced by the respective 325 
monocultures [51]. Moreover, soluble factors secreted by one cell type can stimulate 326 
the secretion of cytokines or chemokines by the other cells in the absence of direct 327 
contact. In fact, conditioned medium from B. abortus-infected monocytes induces IL-328 
8 and MCP-1 secretion by lung epithelial cells, and this effect is mediated by TNF-α 329 
or IL-1β. Reciprocally, conditioned medium from Brucella-infected bronchial epithelial 330 
cells induces MCP-1 production by monocytes in a GM-CSF-dependent manner [51]. 331 
Similarly, it has been shown that the production of CCL20 by lung epithelial cells can 332 
be enhanced, and that of hBD2 can be induced, by factors (namely, IL-1β) produced 333 
by Brucella-infected monocytes [52].  334 
As in most infectious diseases, TLR receptors are relevant for the immune 335 
response to Brucella infection [54]. Studies using TLR KO mice have been central for 336 
establishing the role of TLR in the response to airborne Brucella infection. According 337 
to a study in TLR KO mice of C57BL/6 background, TLR2, TLR4 and the MyD88 338 
adaptor molecule (which is involved in the signaling pathway of most TLR) do not 339 
seem to contribute to the control of lung infection in the first two weeks after aerosol 340 
exposure to B. melitensis. In contrast, the three molecules seem to have a role in the 341 
control of pulmonary infection from week 4 onwards, suggesting a contribution via 342 
their impact on adaptive immunity [55]. A similar study using TLR KO mice of BALB/c 343 
background and intranasal B. abortus infection showed a clear trend to a reduced 344 
control of lung infection at two weeks p.i. in TLR2 KO mice, although differences did 345 
not reach statistical significance [56]. In contrast, the lung burdens in TLR4 and TLR9 346 
KO mice were very similar to the wild type controls. In another study, bacterial counts 347 
in AM and lung homogenates obtained at one week p.i. from mice intratracheally 348 
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infected with B. abortus were significantly higher in TLR2 KO animals than in 349 
C57BL/6 controls [47]. Therefore, despite some discrepancies probably related to 350 
differences in the infection models used, the available studies suggest that TLR are 351 
involved in the early and/or late control of pulmonary Brucella burden after respiratory 352 
infection. The mechanisms by which TLR signaling contributes to the control of 353 
pulmonary Brucella infection have not been established. Several studies suggest that 354 
TLR are involved in the production of proinflammatory cytokines in the lungs of 355 
Brucella-infected mice. However, mice infected intratracheally with B. abortus show a 356 
limited inflammatory response in the lungs during the first week p.i., a phenomenon 357 
related to the expression of bacterial proteins (BtpA and BtpB) that can modulate 358 
TLR signaling [28]. Of note, the lungs from mice infected with a double mutant for Btp 359 
proteins present a stronger inflammatory infiltrate than those infected with the wild 360 
type strain of B. abortus, and the pulmonary levels of proinflammatory cytokines are 361 
also higher in the former. This increased inflammation, however, did not reduce the 362 
bacterial burden in the lungs of mice infected with the Btp mutant as compared to 363 
those infected with the wild type strain [28]. In contrast, the expression of Btp 364 
proteins conferred a survival advantage in the context of a stronger lung inflammation 365 
induced by LPS from E. coli. Therefore, it may be possible that TLR-mediated 366 
inflammation contributes to the control of pulmonary Brucella infection, but the level 367 
of inflammation attained in the early stages of infection is not enough to produce this 368 
effect. In addition, the contribution of TLR to the early control of pulmonary Brucella 369 
infection mentioned above may operate by mechanisms alternative or 370 
complementary to the induction of proinflammatory cytokines.   371 
 Besides TLR, other innate sensors may contribute to the recognition of 372 
Brucella infection and the elicitation of immune responses in the lung. 373 
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Inflammasomes are cytosolic multimeric complexes that mediate the cleavage of pro-374 
IL-1β and pro-IL-18 into their mature active forms [57]. Inflammasomes include 375 
caspase-1 (which mediates the cleavage of pro-IL-1β) and a sensor component 376 
(such as NLRP3, NLRC4, AIM2, etc.) responsible for detecting microbial components 377 
(PAMPs) or cellular damage (DAMPs), and may also include an adaptor molecule 378 
that connects the first two. Upon activation, inflammasomes mediate the proteolytic 379 
cleavage of pro-IL-1β into mature IL-1β, which is the form of the cytokine that can be 380 
secreted. IL-1β has a central role in the early pulmonary immune response to inhaled 381 
pathogens, as it induces the expression of several chemokines and adhesion 382 
molecules, enhances the phagocytic activity of neutrophils and monocytic cells, and 383 
increases the production of reactive oxygen species [58]. Of note, IL-1β levels were 384 
increased in the first days p.i. in lung homogenates and bronchoalveolar lavage fluid 385 
(BALF) of mice intratracheally inoculated with B. abortus, but were comparatively 386 
reduced in caspase-1 KO mice [59]. Interestingly, the pulmonary CFU numbers were 387 
higher in mice lacking the IL-1 receptor (IL-1R) than in wild type mice, and the same 388 
was true for mice lacking some inflammasome components (caspase-1, AIM2, 389 
NLRP3). As mentioned, one of the protective functions of IL-1β is to induce the 390 
expression of chemokines in lung cells. Notably, the levels of CXCL1 (KC) and the 391 
number of neutrophils in BALF during the first days p.i. were significantly reduced in 392 
caspase-1 KO mice as compared to controls. Therefore, this study shows that the 393 
NLRP3 and AIM2 inflammasomes, probably through their ability to induce IL-1β 394 
maturation, are involved in pulmonary innate immune protective mechanisms against 395 
respiratory B. abortus infection. At variance with the protective role of IL-1R found in 396 
this study, a study on intranasal B. melitensis infection did not find increased CFU 397 
counts in the lungs of mice deficient for IL-1R, IL-6, TNF-α, or CCR2 [60]. This 398 
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discrepancy regarding the role of IL-1R may relate to the differences between both 399 
studies in the Brucella species, the infection route and the infecting dose.  400 
Taken together, these data show that lung cells are susceptible to Brucella 401 
invasion and intracellular replication. This pathogen exhibits numerous PAMPs that 402 
can be recognized by innate immune receptors (TLR and inflammasomes) in airways 403 
epithelial cells and AM. These cells secrete cytokines, chemokines and antimicrobial 404 
peptides that would be expected to exert a rapid control of the infection. The efficacy 405 
of these responses, however, is hampered by several characteristics and virulence 406 
factors of the pathogen, including its ability to survive for long periods in infected 407 
cells, its resistance to beta-defensins, and its capacity to modulate TLR-dependent 408 
cytokine responses. Innate immune responses of lung cells to Brucella and the main 409 
mechanisms used by the pathogen to evade such responses are summarized in 410 
Figure 1. 411 
4.2. Adaptive immune response 412 
Brucella is able to evade the adaptive immune response allowing it to establish a 413 
chronic infection. Although the mucosal immune system represents the first line of 414 
defense against Brucella infection in nature, only very few studies have characterized 415 
the adaptive immune response during respiratory infection. Hanot Mambres et al. 416 
evaluated the immune response after primary and secondary i.n. infection of 417 
C57BL/6 mice with virulent B. melitensis [60]. Using genetically deficient mice, they 418 
demonstrated that TNF-α, MHC-II and IFN-ɣR deficiencies impair the late control in 419 
the lungs after primary infection. In addition, IL-17RA deficiency was associated with 420 
a higher bacterial burden in the lungs at day 5 p.i., a time at which IFN-ɣR deficiency 421 
had no impact. In IFN-ɣR KO mice the bacterial burden on all organs tested 422 
increases over time, and all animals die after 35 days p.i. These results demonstrate 423 
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that functional IFN-ɣ is crucial for late control during primary infection. Primary 424 
infection induces development of a protective memory that limits the dissemination of 425 
bacteria from the lungs to the systemic organs after secondary infection. Only 426 
deficiency in TCR-β affects the protective immune response against secondary 427 
infection [60]. Notably, MHC-II or TAP-1 deficiency did not affect the efficiency of the 428 
protective immune response, suggesting that both CD4+ and CD8+ α/β+ T cells are 429 
equally capable to mount a protective immune response against i.n. Brucella 430 
infection. Although IL-12p35 deficiency did not affect the protective memory, IL-17A 431 
neutralization in IL-12p35-/- mice affected the protection conferred against Brucella 432 
challenge, which suggests that the reduced IFN-γ-mediated response can be 433 
compensated for by an IL-17A-mediated response. This study demonstrates that 434 
CD4+ T cells are essential for the development of a protective memory response 435 
against i.n. secondary infection. In addition, CD8+ T cells can compensate for the 436 
absence of CD4+ T cells to generate protection against i.n. Brucella infection.  437 
Recently, a study showed that, in a mouse model of allergic asthma, the 438 
development of the dominant IL-4 (Th2) immune response favors the growth of 439 
Brucella in the lungs of infected animals [61]. This result confirms the relevance of 440 
the Th1 immune response in the control of Brucella in the lung. 441 
TLR activation is essential for the cellular adaptive immune response, as it 442 
induces maturation of antigen presenting cells (APC), and improves antigen 443 
presentation and cytokine production. The cytokine profiles produced by APC 444 
determinate the differentiation of CD4+ T cells into Th1 or Th2 cells. In vivo studies 445 
demonstrated that TLR2, TLR4 and MyD88 signaling are required for efficient 446 
clearance of Brucella from lung following aerosol challenge [59]. Although not 447 
experimentally demonstrated, deficiency in these TLRs is likely to affect 448 
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differentiation of the cellular immune response to a Th1 profile required for efficient 449 
control of Brucella from lung [38]. 450 
As mentioned, AM constitute the main cellular target of inhaled brucellae. Like 451 
macrophages located in other tissues, AM processes microbial antigens and displays 452 
antigenic peptides in the context of MHC molecules for recognition by specific T cells. 453 
IFN-γ activates macrophages and induces their expression of MHC-II molecules, 454 
resulting in enhanced antigen presentation to specific CD4+ T cells. Therefore, 455 
pathogens that can induce downregulation of IFN-γ-induced MHC-II expression in 456 
macrophages can hinder the recognition of infected cells by specific T lymphocytes, 457 
thereby preventing some adaptive immune responses. Interestingly, in vitro studies 458 
have demonstrated that B. abortus infection downregulates the expression of MHC-II 459 
molecules induced by IFN-γ in AM from BALB/c and C57BL/6 mice [47]. The same 460 
reduction was induced by HKBA or L-Omp19, and it was shown to be mediated by 461 
TLR2 recognition. In addition, either L-Omp19 or HKBA reduced the antigen 462 
presentation to T lymphocytes by AM [47]. Downmodulation of MHC-II expression by 463 
B. abortus may contribute to its persistence for a long time in the lungs of infected 464 
mice. The main adaptive immune responses involved in the control of Brucella 465 
infection in the lung, and the evasion mechanism just described, are depicted in 466 
Figure 1. 467 
Brucella respiratory infection generates a specific humoral immune response. An 468 
increase in specific antibodies has been observed in the murine and rhesus macaque 469 
models following respiratory challenge [42,55,60]. Pei et al. demonstrated that TLR2 470 
and TLR4 are required to generate early specific IgG, but not during the last stages 471 
of infection (10 weeks post-challenge) in mice following aerosol exposure to B. 472 
melitensis [55]. TLR2 and TLR4 do not participate in IgA secretion and are only 473 
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required transiently for IgM production. In contrast, MyD88 is indispensable for the 474 
production of specific IgG during all times tested. However, B cell deficiency does not 475 
affect the bacterial burden in tissue during primary and secondary i.n. infection with 476 
B. melitensis. This demonstrates that humoral immunity does not play a crucial role 477 
in the control of i.n. Brucella infection in the mouse model [60].  478 
 479 
5. Vaccination against inhalational brucellosis 480 
Brucellosis can be naturally acquired by Brucella inhalation in both human and 481 
animals, therefore, numerous efforts have been carried out in the last decades to 482 
evaluate the protection conferred by approved and novel vaccines against 483 
inhalational brucellosis. As mentioned, Brucella can enter through the respiratory 484 
mucosa from where it spreads systemically, so an ideal vaccine should be able to 485 
elicit mucosal protective immune responses to eliminate or reduce the spread of the 486 
bacteria, but it should also generate a systemic protective response to prevent 487 
infection of peripheral organs. 488 
Currently, the vaccines in use for livestock are based on live attenuated strains 489 
that prevent disease caused by B. melitensis (strain Rev.1) and B. abortus (strains 490 
S19, RB51). Smither et al. demonstrated that subcutaneous (s.c.) administration of 491 
the strain Rev.1 reduces the bacterial burden in the spleen but not in the lung or liver 492 
of mice challenged with aerosolized B. melitensis 16M. However, i.n. immunization 493 
with Rev.1 strain significantly reduces the burden of B. melitensis in the lung and 494 
spleen at all times tested [30]. B. abortus strain RB51 is a rough strain approved to 495 
prevent cattle brucellosis in the USA and other countries, and is preferably 496 
administered by the s.c. route. Olsen et al. have shown that i.p. immunization with 497 
RB51 strain does not protect from aerosol challenge with virulent B. abortus in mice 498 
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[29]. In other study, administration of RB51 or the same strain over-expressing 499 
superoxide dismutase by different routes (i.n., i.p., intradermal, s.c.) and prime-boost 500 
strategies did not protect against i.n. B. abortus infection in mice [62]. However, i.n. 501 
administration of RB51 together with TLR agonists (TLR2 or TLR4) significantly 502 
increased protection in the lung [63], demonstrating that potentiating the immunity 503 
with adjuvants, like TLR agonists, may be a useful strategy to improve the 504 
performance of attenuated vaccines against respiratory infection. B. abortus strain 505 
S19 is a smooth strain approved to prevent cattle brucellosis and is frequently 506 
administered by the s.c. route. It has been shown that i.n. administration of S19 507 
reduces the load of pathogenic B. abortus in the lung but does not modify the burden 508 
of bacteria in the spleen [62]. These results demonstrate that the approved 509 
attenuated vaccines against B. abortus, which have been shown to elicit protection 510 
against parenteral challenge in mice models, do not protect efficiently against 511 
respiratory challenge, which would explain at least in part their limited efficiency in 512 
the protection of livestock.  513 
Other studies have evaluated the protection against respiratory infection 514 
conferred by experimental vaccines based on mutant strains of Brucella. In the 515 
murine model, oral administration of B. melitensis WR201 managed to reduce the 516 
bacterial load in lung and liver after intranasal challenge with B. melitensis 16M [64]. 517 
Similarly, i.n. vaccination of mice with high doses of B. melitensis ΔznuA (109 518 
CFU/mice) conferred strong pulmonary protection against the i.n. challenge with B. 519 
melitensis 16M and reduced its systemic dissemination [65]. Kahl-McDonagh et al. 520 
demonstrated that B. abortus Δasp24 and B. melitensis Δasp24, administered by i.p. 521 
route, protect mice against homologous and heterologous aerosol challenge infection 522 
[31]. However, the reduction in the burden of virulent B. abortus in the lung, although 523 
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significant, was not as marked as that observed in the spleen, or in the organs of 524 
animals challenged with B. melitensis. These results and those described above 525 
show that the ability of these experimental vaccines to protect the lung from Brucella 526 
infection may differ depending on the infecting Brucella species. In unvaccinated 527 
mice the pulmonary load of aerosolized B. melitensis decreases more rapidly 528 
compared to B. abortus [31]. This different behavior may also impact on the efficacy 529 
of vaccination-induced clearance of lung bacteria. 530 
While immunization with either approved or experimental vaccines based on 531 
live mutant strains of Brucella may confer protection against respiratory challenge 532 
with pathogenic brucellae, the use of such vaccines is associated with several safety 533 
concerns that limit their use in animals and preclude their use in humans. Besides 534 
their potential for reversion to a wild type phenotype, many of these strains still 535 
produce clinical manifestations in humans and in some animals (e.g., abortion in 536 
pregnant females). Moreover, the strains B. abortus RB51 and B. melitensis Rev.1, 537 
currently approved for use in animal vaccination, are resistant to antibiotics 538 
commonly used to treat human brucellosis. In the search for an efficient and safe 539 
vaccine capable of protecting against respiratory challenge by Brucella, the 540 
effectiveness of inactivated vaccines and subunit vaccines has been studied. Oral 541 
immunization with different doses of gamma-irradiated B. neotomae showed that a 542 
high dose (1011 CFU) is required to provide protection against i.n. B. abortus 543 
challenge [66]. On the other hand, i.n. immunization of mice with B. melitensis LPS 544 
together with outer membrane proteins of N. meningitidis group B as adjuvant, 545 
induced a strong systemic and mucosal immune response that could control the 546 
spread of Brucella to spleen and liver after respiratory infection, but was unable to 547 
control infection at the lung level [67].  548 
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A study that evaluated the immunogenicity and protection conferred by nasal 549 
administration of Omp31 peptides in mice demonstrated a reduction in lung load 550 
following the i.n. challenge with B. melitensis. Despite these promising results, 551 
vaccination failed to control systemic dissemination [68]. In a recent study performed 552 
by our group, i.n. administration of the B. suis BtaF adhesin in mice conferred high 553 
levels of protection against intragastric B. suis infection. Unlike what was observed 554 
for oral infection, nasal vaccination with BtaF did not protect against B. suis 555 
respiratory infection [33]. In another recent study, i.n. immunization of mice with a 556 
chitosan-based vaccine formulated with well-known Brucella antigens (SodC, 557 
Omp19, BLS and PrpA) with or without Brucella LPS generated a humoral and 558 
cellular immune response that reduced the burden of B. abortus 544 in lungs and 559 
spleen after nasal challenge [69]. All these findings make it clear that protective 560 
immune responses against Brucella spp. inhalational infection are intimately related 561 
to the nature and composition of vaccines, the immunization route, and the Brucella 562 
species used for challenge. 563 
 564 
Currently, little is known about the immune response needed to achieve lung 565 
protection during respiratory Brucella infection. Some studies concluded that CD8+ T 566 
cells are critical for the resolution of infection, whereas others suggested that they 567 
are dispensable [65,70]. Clapp et al. demonstrated that CD8+ T cells, but not CD4+ 568 
cells or IL-17, are essential for protection against respiratory infection [65]. In contrast 569 
with this study, Yingst et al. demonstrated that CD8 KO mice are protected from 570 
nasal challenge by oral vaccination with a live attenuated strain of B. melitensis [70]. 571 
As mentioned, in the murine model pulmonary protection against aerosolized B. 572 
melitensis is conferred by IFN-ɣ-producing CD4+ T cells [60]. However, in the 573 
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absence of this cellular population, CD8+ T cells can exert the protective response in 574 
the lung. This compensatory mechanism between both cell populations could explain 575 
the discrepancies in lung protection studies against inhalational brucellosis. 576 
Recently, Wang et al. demonstrated that vaccination of mice with a strategy of 577 
oral prime and nasal boost with high doses of a double-mutant of B. abortus called 578 
znBAZ (which lacks znuA and norD) confers efficient protection against nasal 579 
infection with virulent B. abortus 2308, and its protective efficacy is superior to that of 580 
the RB51 vaccine [71]. CD8+ T cells were essential for znBAZ-mediated protection 581 
against the nasal challenge. In contrast, CD4+ T cells were required for protection 582 
conferred by RB51. The znBAZ vaccine induces IFN-γ and TNF-α positive tissue- 583 
resident memory CD8+ T cells (CD8+ TRM), as well as polyfunctional cells in the lung. 584 
CD8+ TRM cells able to produce IL-17 were also induced by vaccination with znBAZ, 585 
but neutralization of IL-17 in vivo did not affect protection. Vaccination with RB51 586 
failed to induce CD4+ and CD8+ TRM cells in the lung, which may explain its limited 587 
ability to protect against respiratory infection by B. abortus. These results 588 
demonstrate that the generation of TRM cells is an important aspect to consider in the 589 
development of new mucosal vaccines for respiratory Brucella infection. 590 
In summary, lung protection studies demonstrate the difficulty of obtaining a 591 
vaccine capable of generating protective responses against inhalational Brucella 592 
infection. A possible explanation for this problem may be the inability of the tested 593 
vaccines to generate an efficient innate and adaptive immune response in the 594 
context of the lung mucosal microenvironment. Another possible explanation in the 595 
case of live B. abortus vaccines is the ability of Brucella to suppress the innate 596 
immune response in the lung as described by Hielpos et al. [28], which could affect 597 
the ability of DCs to induce protective cellular immune responses. The intracellular 598 
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nature of Brucella can also contribute to the inability of vaccines to induce efficient 599 
protection. Once inhaled, B. abortus can infect and replicate in AM and pulmonary 600 
epithelial cells without inducing potent activation of innate immunity [44,46,47,51]. 601 
This could allow the bacteria to avoid clearance or detection by adaptive immunity 602 
effector mechanisms in a tolerogenic mucous environment. The studies reviewed 603 
here suggest the need for further research to develop an efficient vaccine for 604 
inhalational brucellosis. 605 
 606 
6. Concluding remarks 607 
Understanding the pathogenesis and immune response to inhalational Brucella 608 
infection is an important issue given the prevalence of brucellosis and the frequency 609 
of infection by the respiratory route in humans and animals. Data from human cases 610 
and animal models have clearly shown that Brucella can rapidly disseminate from its 611 
pulmonary site of entry to peripheral organs. In the lung, however, the inflammatory 612 
reaction is scarce. Pieces of evidence collected from these studies help to 613 
understand the reasons for the efficiency of the respiratory route for Brucella 614 
infection. On the one hand, at least some Brucella species seem to establish 615 
persistent infections in lung tissues. This may be related to the ability of Brucella to 616 
survive and replicate in lung epithelial cells and AM, its capacity to modulate the 617 
pulmonary inflammatory response, its resistance to locally produced antimicrobial 618 
peptides, and its ability to downmodulate MHC-II expression and antigen 619 
presentation by AM. On the other hand, several studies have shown that Brucella 620 
can rapidly reach the bloodstream and peripheral organs from its initial site of entry in 621 
the lungs. This dissemination seems to be executed, at least in part, by infected AM 622 
that act as Trojan horses, and happens even before an enhanced innate immune 623 
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response can be mounted in the lungs. Therefore, although pulmonary innate 624 
receptors (TLRs, inflammasomes) and cytokine responses have been shown to exert 625 
some control of Brucella infection, these factors are insufficient to avoid the systemic 626 
dissemination of the pathogen from the lungs, at least during the early phase of lung 627 
infection. Therefore, the challenge is to develop human vaccines that could ideally 628 
control pulmonary Brucella infection and could also prevent systemic spread. The 629 
studies performed with live attenuated strains in animal models have shown the 630 
difficulty to protect efficiently against respiratory challenge. Nevertheless, it has been 631 
shown that IL-17 is involved in the early control of the pulmonary infection, and IFN-γ 632 
is crucial for late control in all organs after respiratory challenge. In addition, both 633 
CD4+ and CD8+ cells seem to mediate these responses. Therefore, it can be 634 
presumed that lung colonization and systemic spread of Brucella after respiratory 635 
infection could be prevented by immunization protocols eliciting these types of 636 
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Figure legends 861 
 862 
Figure 1. Interactions of Brucella spp. with lung cells. The scheme summarizes 863 
the results obtained from in vivo studies in mice and in vitro studies performed with 864 
human and mouse cells, using different Brucella species. Upon inhalation Brucella 865 
would interact with alveolar and bronchial epithelial cells and alveolar macrophages 866 
(AM) eliciting the secretion of cytokines and chemokines (solid red lines). In turn, 867 
some of these soluble factors would stimulate the production of chemokines and 868 
defensins (hBD2) by adjacent cells (dashed lines). Some alveolar macrophages 869 
containing viable Brucella can migrate to the mediastinal lymph nodes (MdLN), 870 
presumably contributing to the systemic dissemination of the pathogen. In the lymph 871 
node, CD4+ and CD8+ naïve T cells are stimulated by antigen presenting cells 872 
(APC), the identity of which remains to be established. Th1, Th17 and CD8+ cells 873 
have been shown to contribute to Brucella control in the lung. Brucella opposes 874 
several evasion mechanisms to these immune responses (blue lines) including the 875 
downmodulation of TLR signaling, the resistance to beta-defensins and the 876 
downmodulation of MHC-II expression in alveolar macrophages. ATI: type I alveolar 877 
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